Ferenc L. Boldog

This paper describes the development and cGMP manufacturing of an HIV vaccine candidate for clinical trials, demonstrating scalable production and quality control.

This paper introduces a method using orthogonal transposons to iteratively modify the CHO genome for therapeutic development, achieving stable and predictable genetic modifications.

This paper shows that using the Leap-In transposon platform improves predictability in developing bispecific antibody-producing cell lines by enabling stable pools with predictable productivity and heterodimer fractions.